Erythropoietin Therapy for Children With Cerebral Palsy

Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind

This randomized placebo-controlled trial aims to investigate the efficacy and safety of erythropoetin for children with cerebral palsy.

Cerebral palsy is a disorder of movement and posture resulted from a nonprogressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability.

Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain. The main mechanism of erythropoietin is supposed as follows;

1. Neuroprotection effect
2. Angiogenesis
3. Anti-inflammation.

On the basis of many experimental studies, erythropoietin is suggested as a therapeutic method for cerebral palsy.

Inclusion Criteria:

• Cerebral Palsy
• Abnormal Muscle Tone
• Abnormal Brain MRI
• Willing to Comply with All Study Procedure

Exclusion Criteria:

• Known Genetic Disorder
• Other Etiologies Contributing Developmental Delay
• Coagulopathy
• Initial high Erythropoietin level in Serum
• Previous Erythropoietin Treatment before 3 months
• Presence of Drug Hypersensitivity Related to the Study Remedy
• Intractable Seizure Disorder
• Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation